Literature DB >> 4116993

Rifampicin, ethambutol and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years chemotherapy.

M Aquinas, K M Citron.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4116993     DOI: 10.1016/0041-3879(72)90012-8

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


× No keyword cloud information.
  7 in total

1.  A comparison of rifampicin, ethambutol or PAS in short-term monotherapy in pretreated cavitary pulmonary tuberculosis.

Authors: 
Journal:  Pneumonologie       Date:  1975-12-12

2.  Ocular toxicity from ethambutol.

Authors:  K M Citron; G O Thomas
Journal:  Thorax       Date:  1986-10       Impact factor: 9.139

Review 3.  Prospects of retreatment of chronic resistant pulmonary tuberculosis patients. A critical review.

Authors:  M Zierski
Journal:  Lung       Date:  1977       Impact factor: 2.584

4.  Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.

Authors:  Amber Arnold; Graham S Cooke; Onn Min Kon; Martin Dedicoat; Marc Lipman; Angela Loyse; Irina Chis Ster; Thomas S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 5.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

6.  Two unusual cases of severe recalcitrant hypocalcemia due to aminoglycoside-induced hypomagnesemia.

Authors:  Tarun Varma; Ashish Saini; Roopal Panchani; Nitin R Gupta
Journal:  Indian J Endocrinol Metab       Date:  2013-10

7.  Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.

Authors:  J Peter Cegielski; Pei-Chun Chan; Zhiyi Lan; Zarir F Udwadia; Piret Viiklepp; Jae-Joon Yim; Dick Menzies
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.